LncRNA SPRY4‐IT1 regulates breast cancer cell stemness through competitively binding miR‐6882‐3p with TCF7L2

Song, Xinyue; Zhang, Xiaoxue; Wang, Xinnan; Chen, Lianze; Jiang, Longyang; Zheng, Aiping; Zhang, Ming; Zhao, Lin; Wei, Minjie

doi:10.1111/jcmm.14786

Cited by 45 publications

(38 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiRNA sponge is a crucial role of lncRNAs. Recent years, increasing studies have revealed that lncRNAs can regulate tumor progression by sequestering miRNAs thus releasing their downstream target mRNAs and prompting mR-NAs to exert functions [22][23][24]. Here, we applied bioinformatics analysis to screen out the miRNAs that potentially interact with FGD5-AS1.…”

Section: Discussionmentioning

confidence: 99%

Long non-coding RNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFRL1

Fan

Li²,

et al. 2020

Bioscience Reports

View full text Add to dashboard Cite

Long non-coding RNA (lncRNA) FYVE, RhoGEF and PH domain containing 5 antisense RNA 1 (FGD5-AS1) has been reported as an oncogene in colorectal cancer, promoting its tumorgenesis. The present paper focused on searching the potential function of FGD5-AS1 in non-small cell lung carcinoma (NSCLC). There are connections between the expression of lncRNA FGD5-AS1 and human NSCLC tumor growth and progression. Also, the relationships between FGD5-AS1, hsa-miR-107 and mRNA fibroblast growth factor receptor like 1 (FGFRL1) are going to test their interaction in NSCLC cell lines, which may cause a series of biological behaviors of NSCLC cells. qRT-PCR analysis was conducted to test the expression of RNAs in different situation. CCK-8 experiment and clone formation assay were performed to assess proliferation of NSCLC cells. Also, connection between FGD5-AS1 and hsa-miR-107 were investigated by luciferase reporter assay and RNA pull-down assay. Rescue experiments were performed to verify the modulating relationship between FGD5-AS1, hsa-miR-107 and FGFRL1. High-level expression of FGD5-AS1 was found in NSCLC. FGD5-AS1 may promote the proliferation of NSCLC cells. Also, the combination between hsa-miR-107, FGD5-AS1 and NSCLC have been proved, which means they can play an interaction function in NSCLC cells. Thence, we concluded that lncRNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFRL1.

show abstract

Section: Discussionmentioning

confidence: 99%

Long non-coding RNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFRL1

Fan

Li²,

et al. 2020

Bioscience Reports

View full text Add to dashboard Cite

show abstract

“…Promotes stemness by sequestering miR-6882-3p which targets TCF4, allowing initiation of canonical Wnt signaling [76]. [76] miR-6882-3p…”

Section: Spry4-it1mentioning

confidence: 99%

“…SPRY4-IT1 is an intronic lncRNA transcribed from one of the introns of the SPRY4 gene, which encodes a tumor suppressor [102]. SPRY4-IT1 is upregulated in CD44 high CD24 low ER+ MCF-7 cells and expression of stemness factors OCT4, c-Myc, NANOG and SOX2 are positively correlated with SPRY4-IT1 expression levels [76]. Further analysis revealed that SPRY4-IT1 mediates its stemness promoting effects by acting as a ceRNA to sequester miR-6882-3p [76], which targets TCF7L2/TCF4.Thus, SPRY4-IT1 promotes stemness by promoting the Wnt/β-catenin signaling pathway.…”

Section: Spry4-it1mentioning

confidence: 99%

The Missing Lnc: The Potential of Targeting Triple-Negative Breast Cancer and Cancer Stem Cells by Inhibiting Long Non-Coding RNAs

Brown

Wasson

Marcato

2020

Cells

View full text Add to dashboard Cite

Treatment decisions for breast cancer are based on staging and hormone receptor expression and include chemotherapies and endocrine therapy. While effective in many cases, some breast cancers are resistant to therapy, metastasize and recur, leading to eventual death. Higher percentages of tumor-initiating cancer stem cells (CSCs) may contribute to the increased aggressiveness, chemoresistance, and worse outcomes among breast cancer. This may be particularly true in triple-negative breast cancers (TNBCs) which have higher percentages of CSCs and are associated with worse outcomes. In recent years, increasing numbers of long non-coding RNAs (lncRNAs) have been identified as playing an important role in breast cancer progression and some of these have been specifically associated within the CSC populations of breast cancers. LncRNAs are non-protein-coding transcripts greater than 200 nucleotides which can have critical functions in gene expression regulation. The preclinical evidence regarding lncRNA antagonists for the treatment of cancer is promising and therefore, presents a potential novel approach for treating breast cancer and targeting therapy-resistant CSCs within these tumors. Herein, we summarize the lncRNAs that have been identified as functionally relevant in breast CSCs. Furthermore, our review of the literature and analysis of patient datasets has revealed that many of these breast CSC-associated lncRNAs are also enriched in TNBC. Together, this suggests that these lncRNAs may be playing a particularly important role in TNBC. Thus, certain breast cancer-promoting/CSC-associated lncRNAs could be targeted in the treatment of TNBCs and the CSCs within these tumors should be susceptible to anti-lncRNA therapy.

show abstract

“…The ceRNA (competitive endogenous RNA) hypothesis believes that a large-scale transcriptional regulatory network may be formed between RNAs, which can affect biological processes [23]. Our study is based on the ceRNA hypothesis, that is, cbr3-as1 directly binds to miR-25-3p, thus targeting JNK1 / MEK4, activating MAPK pathway, and ultimately affecting the chemoresistance process of BRCA.…”

Section: Discussionmentioning

confidence: 99%

“…The assay was carried out according to the method mentioned in the previous study [23]. We collected BRCA tissues of patients from the First A liated Hospital of China Medical University for ISH assay.…”

Section: Ish (In Situ Hybridization) and Ihc (Immunohistochemistry)mentioning

confidence: 99%

LncRNA CBR3-AS1 Regulates of Breast Cancer Drug Sensitivity as a Competing Endogenous RNA Through the JNK1/MEK4‑Mediated MAPK Signal Pathway

Zhang¹,

Wang²,

Jiang³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Adriamycin (ADR) resistance is one of the main obstacles to improve the clinical prognosis of breast cancer (BRCA) patients. Long non-coding RNAs (lncRNAs) can regulate cell behavior, but the role of these RNAs in anti ADR of BRCA remains unclear. Here we aim to investigate the imbalance of a particular long noncoding RNA, lncRNA CBR3 antisense RNA 1 (CBR3-AS1), and its role in ADR resistance.Methods: Microarray analysis of ADR-resistant BRCA cells was performed to identify CBR3-AS1. CCK8 assay and colony formation assay were used to detect the sensitivity of BRCA cells to ADR. Dual-luciferase reporter, RNA pull down, IHC and Western blot were used to verify the relationship between CBR3-AS1, miRNA and target genes. In vivo, the effect of CBR3-AS1 on BRCA resistance was observed by xenograft tumor model. The role of CBR3-AS1 in influencing ADR sensitivity was verified by clinical BRCA specimens, TCGA, CCLE, and GDSC databases.Results: Here, we found that lncRNA CBR3-AS1 was significantly increased in BRCA tissues and was closely correlated with poor prognosis. CBR3-AS1 overexpression promoted ADR resistance in BRCA cells in vitro and in vivo. Mechanistically, we identified that CBR3-AS1 functioned as a competitive endogenous RNA by acting as a molecular sponge of miR-25-3p. MEK4 and JNK1 of MAPK pathway were the direct downstream proteins of CBR3-AS1 / miR-25-3p axis in BRCA cells.Conclusions: In summary, our findings demonstrate that CBR3-AS1 plays a critical role in the chemotherapy resistance of BRCA by mediating the miR-25-3p, MEK4/JNK1 regulatory axis. The potential of CBR3-AS1 as an oncogene and therapeutic biomarker of BRCA was identified.

show abstract

LncRNA SPRY4‐IT1 regulates breast cancer cell stemness through competitively binding miR‐6882‐3p with TCF7L2

Cited by 45 publications

References 40 publications

Long non-coding RNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFRL1

Long non-coding RNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFRL1

The Missing Lnc: The Potential of Targeting Triple-Negative Breast Cancer and Cancer Stem Cells by Inhibiting Long Non-Coding RNAs

LncRNA CBR3-AS1 Regulates of Breast Cancer Drug Sensitivity as a Competing Endogenous RNA Through the JNK1/MEK4‑Mediated MAPK Signal Pathway

Contact Info

Product

Resources

About